Highlights From the ISTH 2021 Congress
Liver Safety Case Report From the Phase 3 HOPE-B Gene Therapy Trial in Adults With Hemophilia B
M. Schmidt1, G.R Foster2, M. Coppens3, H. Thomsen1, D. Cooper4, R. Dolmetsch4, E.K Sawyer4, L. Heijink5, S.W Pipe6
1GeneWerk GmbH, Heidelberg, Germany
2Barts Liver Centre, Queen Mary University of London, London, United Kingdom
3Amsterdam University Medical Center, Amsterdam, Netherlands
4uniQure Inc, Lexington, United States
5uniQure BV, Amsterdam, Netherlands
6University of Michigan, Ann Arbor, United States
Key Data Points
- 69-year-old, white non-Hispanic male with moderately severe Hemophilia B
- 1980-Diagnosed with HBV (+ve for anti-HBs, and anti-HBc and anti-HBe antibodies)
- 1983-Diagnosed with non-A/non-N hepatitis
- 2003-Confirmed positive for HCV when testing available
- 2015-Evaluated for HCV eradication therapy, genotype 1a, no significant fibrosis (Fibroscan 5.7 kPa)
- 2015-Treated with paritaprevir/ombitasvir/ritonavir, dasabuvir, and ribavirin; achieving a sustained virologic response
- Social history notable for prior smoking, alcohol consumption of 0-2 units/week
- Familial history notable for cancer
Liver-related medical history of a patient with hemophilia B in the HOPE-B trial who experienced hepatocellular carcinoma while participating in the study. His medical history contains several risk factors for the development of HCC, including hepatitis B and C, advanced age, and alcohol consumption.
At 1-year post-infusion, a per protocol ultrasound revealed a subcapsular liver lesion. This table summarizes the subsequent molecular integration site analysis and whole genome sequencing done on resected tumor tissue, including expected findings if the HCC was dependent on (column 1) or independent of (column 2) AAV integration. The actual findings of the analyses are shown in column 3.
RELATED CONTENT
Live Webinar: Ask Me Anything! Gene Therapy in Hemophilia - September 2026
Presented by Flora Peyvandi, MD, PhD, Vincenzo La Mura, MD, Marica Moro, RN, and Cristina Novembrino...
New Frontier Forum — How the Past Informs Our Future With Hemophilia Gene Therapy
Presented by Flora Peyvandi, MD, PhD, Vincenzo La Mura, MD, Marica Moro, RN, and Cristina Novembrino...
New Frontier Forum — Novel Advances in Gene Therapy for Hemophilia
Presented by Flora Peyvandi, MD, PhD, Vincenzo La Mura, MD, Marica Moro, RN, and Cristina Novembrino...
Live Webinar: Ask Me Anything! Gene Therapy in Hemophilia - June 2026
Presented by Flora Peyvandi, MD, PhD, Vincenzo La Mura, MD, Marica Moro, RN, and Cristina Novembrino...
Gene Therapy in Hemophilia: Clinical Care Strategies for Gene Therapy
Presented by Flora Peyvandi, MD, PhD, Vincenzo La Mura, MD, Marica Moro, RN, and Cristina Novembrino...
Gene Therapy in Hemophilia
Presented by Guy Young, MD...
Hemophilia Gene Therapy — Readying for Clinical Care: Webinar Series
Presented by Johnny Mahlangu, BSc, MBBCh, MMed, FCPath...
Preparing for Practice Readiness in Gene Therapy for Hemophilia
Wolfgang Miesbach, MD and Steven W. Pipe, MD...
Recent Advances in Gene Therapy for Hemophilia Clinical Trials
Presented by Annette von Drygalski, MD, PharmD and Guy Young, MD...
Gene Therapy in Hemophilia: An APSTH ISTH Sponsored Symposium
Presented by Pantep Angchaisuksiri, MD, Flora Peyvandi, MD, PhD, Steven W. Pipe, MD, and Alok...
Hemophilia Gene Therapy - Key Components of Clinical Care
Presented by Michael Makris, MA, MB BS, MD, FRCP, FRCPath, Wolfgang Miesbach, MD, PhD, and Flora...
